Drugs / ROVAFOVIR ETALAFENAMIDE
ROVAFOVIR ETALAFENAMIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03472326 | Apr 2018 → Dec 2019 | HIV infectious disease | Gilead Sciences | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ROVAFOVIR ETALAFENAMIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594257 ↗ |
| Known as | GS-9131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03472326 ↗ |
| Known as | GS-9131 citrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594257 ↗ |
| Known as | GS-9148 PHOSPHONOAMIDATE PRODRUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594257 ↗ |
| Known as | Rovafovir etalafenamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594257 ↗ |
| Known as | ROVAFOVIR ETALAFENAMIDE CITRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594257 ↗ |
| Modality | Small molecule | — CHEMBL4594257 ↗ |
| Route | Oral | “Tablet(s) administered orally once daily” NCT03472326 ↗ |